STAT March 21, 2024
Andrew Joseph

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test
Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine
BioAro Announces Real Time DNA Decoding Technology
23andMe: What If …
23andMe CEO Anne Wojcicki considers taking company private

Share This Article